Utreglutide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Utreglutide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Utreglutide can convert its Synthetic peptide profile and GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Utreglutide (query alias: Utreglutide) |
|---|---|
| Modality / target | Synthetic peptide; GLP-1R; GLP-1R agonists |
| Highest global status | Phase 2 |
| Originator | Sun Pharmaceutical Industries Ltd. |
| Active developers | Sun Pharmaceutical Industries Ltd. |
The MCP disease footprint includes Obesity, Diabetes Mellitus, Type 2. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| CTRI/2026/05/110853 | Phase 1 | Not Yet Recruiting | 40 | Primary endpoint not disclosed in English source |
| NCT07385547 | Phase 1 | Recruiting | 40 | Primary endpoint not disclosed in English source |
| NCT07282743 | Phase 2 | Recruiting | 285 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity—A Multiple Ascending Dose Study
Phase 1; n=12; evaluation: Positive. Reported fields: Body weight(29-day) = -2.9 kg (SD, 1.7); Body weight(29-day) = -4.6 kg (SD, 1.5)
A single ascending dose study of the novel GLP-1 receptor agonist GL0034 (utreglutide) in individuals with obesity without diabetes
Phase 1; n=24; evaluation: Positive. Reported fields: Adverse Event: gastrointestinal adverse events = The common utreglutide-related adverse events were gastrointestinal with dose-dependent nausea, decreased appetite and vomiting. No injection site reactions or any other adverse events were noted.
A Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes
Not Applicable; n=24; evaluation: Positive. Reported fields: Adverse Event: gastrointestinal adverse events = Most common GL-related adverse events were gastrointestinal with dose-dependent nausea, decreased appetite and vomiting ; Adverse Event: gastrointestinal adverse events = Most common GL-related adverse events were gastrointestinal with dose-dependent nausea, decreased appetite and vomiting
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Utreglutide addresses Obesity, Diabetes Mellitus, Type 2. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 156 matched transaction record(s) under the scope “target-level comparable: GLP-1R.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: GLP-1R records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-09-09 | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Phase 2 | Financial terms not disclosed |
| 2026-08-21 | Transaction title not available in English source | Phase 2 | US$161.9M stated total |
| 2026-08-20 | Sandoz, Biolab join Brazil’s growing semaglutide market | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Anti-overdosing compositions and uses thereof”. The milestone feed surfaced a patent-application signal described as “Composition comprising a GLP1r agonist and engineered extracellular vesicles comprising adiponectin, and uses thereof”. The milestone feed surfaced a patent-application signal described as “Methods for treating obesity and increasing weight loss”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Clinical differentiation versus current standards and pipeline competitors
- Safety, dose optimization, and long-term tolerability
- Patent scope, territorial rights, manufacturing, and commercial positioning
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
